Elutia Inc. (ELUT)vsEdwards Lifesciences Corp (EW)
ELUT
Elutia Inc.
$0.85
-3.52%
HEALTHCARE · Cap: $38.95M
EW
Edwards Lifesciences Corp
$89.72
+0.45%
HEALTHCARE · Cap: $49.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 52182% more annual revenue ($6.51B vs $12.46M). ELUT leads profitability with a 400.2% profit margin vs 15.4%. EW earns a higher WallStSmart Score of 55/100 (C).
ELUT
Hold41
out of 100
Grade: D
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.2%
Fair Value
$0.94
Current Price
$0.85
$0.09 discount
Margin of Safety
+69.3%
Fair Value
$257.97
Current Price
$89.72
$168.25 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 221 in profit
Keeps 400 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ELUT
The strongest argument for ELUT centers on Return on Equity, Profit Margin, Debt/Equity. Profitability is solid with margins at 400.2% and operating margin at -184.4%.
Bull Case : EW
The strongest argument for EW centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : ELUT
The primary concerns for ELUT are EPS Growth, Market Cap, Free Cash Flow.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.2x leaves little room for execution misses.
Key Dynamics to Monitor
ELUT carries more volatility with a beta of 0.88 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
ELUT generates stronger free cash flow (-8M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
EW scores higher overall (55/100 vs 41/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Elutia Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?